New PEPFAR Data Show Worrying Declines in Testing and Treatment for H.I.V.

Why It Matters

The contraction in testing and infant treatment threatens to reverse gains in global HIV control and could increase future mortality, underscoring the fragility of US‑funded health initiatives.

Key Takeaways

• PEPFAR testing fell to 17.2 M in Q4 2025, down from 21.9 M
• New HIV diagnoses dropped 78 K, from 385 K to 307 K
• Infant HIV treatment numbers declined, raising mortality risk
• Trump-era shutdown caused flat overall treatment numbers despite prior growth

Pulse Analysis

PEPFAR, launched in 2003, has become the world’s largest single‑disease health program, channeling billions of dollars of U.S. aid to curb HIV/AIDS in more than 50 countries. Its success—saving an estimated 26 million lives—has hinged on a robust cascade of testing, diagnosis, and treatment, especially for vulnerable groups such as pregnant women and infants. By maintaining a steady flow of resources and technical support, the initiative has helped lower infection rates and improve life expectancy across sub‑Saharan Africa, Southeast Asia, and the Caribbean.

The latest State Department figures expose a troubling disruption in that cascade. A 21% drop in testing between Q4 2024 and Q4 2025 means fewer people are entering the care continuum, directly translating into a 20% dip in new diagnoses. With fewer cases identified, the pool of individuals eligible for antiretroviral therapy shrinks, jeopardizing the goal of achieving epidemic control by 2030. Experts point to the Trump administration’s abrupt program suspension and delayed restart as a primary catalyst, highlighting how policy volatility can quickly erode hard‑won public‑health gains.

Beyond the immediate health impact, the data send a cautionary signal to donors and policymakers about the importance of funding stability. Inconsistent financing erodes partner confidence, hampers supply chain reliability, and can trigger a resurgence of infections that would cost more to address later. For the United States, preserving the credibility of its global health leadership means insulating programs like PEPFAR from political swings, ensuring continuous investment, and reinforcing collaborative frameworks with host nations. Such measures are essential to sustain progress and protect the millions who depend on these life‑saving services.